Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) single-dose vials for obesity treatment. Through LillyDirect, Ro will provide patients with streamlined access to this FDA-approved medication at a self-pay price,

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline access to the popular treatment.

Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss drug directly to patients.

Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound. Ro Health is joining other telehealth platforms and Amazon Pharmacy (AMZN) in giving patients access to Lilly's top GLP-1 product by plugging in to the pharmaceutical giant's new direct-to-consumer platform,

Through a new relationship with Eli Lilly, Ro patients can now get easier access to the drugmaker’s discounted, single-dose vials of blockbuster obesity drug Zepbound.Ro said Wednesday that it integrated its technology with Lilly’s direct-to-consumer service LillyDirect so that patients can talk to a doctor,